ReShape Lifesciences (RSLS) announced that on July 8, 2025 the U.S. Patent and Trademark Office, USPTO, will issue U.S. Patent 12,350,179, entitled, “Intragastric Device.” The patent, related to the Company’s application 18/241,151 and notice of allowance received in April, covers claims for an intragastric balloon system, comprising a swallowable capsule with a self-sealing fill valve and a degradable release valve designed to deflate and open the valve around three months after inflation with saline liquid, and configured for natural excretion after deflation, among other claim features. The patent will provide protection into at least January 2031, without accounting for a potential Patent Term Extension.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on RSLS:
- ReShape Lifesciences regains compliance with Nasdaq min stockholders equity
- ReShape announces heacount reduction, progress toward agreement completions
- ReShape Lifesciences granted key international patent in Australia
- ReShape Lifesciences Raises Equity to Avoid Delisting
- ReShape Lifesciences Closes $2.6M Stock Offering